Peptides for Belly Fat: What Actually Works

Belly fat — particularly visceral fat packed around your organs — is the most metabolically dangerous type of fat you can carry. It drives insulin resistance, cardiovascular disease, and chronic inflammation in ways that subcutaneous fat simply doesn’t.

That’s why the question of which peptides for weight loss actually target belly fat specifically is worth asking. Not all weight loss is created equal, and not all peptides work the same way.

Here’s what the clinical data actually shows.

Key Takeaways

• Tesamorelin is the only FDA-approved peptide specifically shown to reduce visceral abdominal fat — cutting visceral adipose tissue by 15-18% over 6-12 months in clinical trials [1][2]
• GLP-1 peptides (semaglutide, tirzepatide) produce the most total weight loss, with roughly 74% of lost weight coming from fat mass, including significant visceral fat reduction [3]
• AOD-9604 showed modest results in Phase 2 trials — about 2.6 kg over 12 weeks — and never received FDA approval [4]
• Growth hormone secretagogues like CJC-1295 and ipamorelin may improve body composition but lack strong direct evidence for targeted belly fat loss

Table of Contents

1. Why Belly Fat Is Different
2. Tesamorelin: The Visceral Fat Specialist
3. GLP-1 Peptides: The Biggest Overall Impact
4. AOD-9604: The GH Fragment
5. Growth Hormone Peptides: CJC-1295 and Ipamorelin
6. MOTS-c: The Metabolic Peptide
7. Comparing the Options
8. Side Effects and Safety
9. FAQ
10. Sources

Why Belly Fat Is Different

There are two types of belly fat, and the distinction matters for understanding how peptides work.

Subcutaneous fat sits between your skin and abdominal wall. It’s the fat you can pinch. It’s cosmetically annoying but relatively benign from a health standpoint.

Visceral fat wraps around your liver, intestines, and other organs deep in the abdominal cavity. You can’t pinch it. It acts almost like an endocrine organ, pumping out inflammatory cytokines and contributing to insulin resistance, type 2 diabetes, and cardiovascular disease [5].

When most people talk about “belly fat,” they’re seeing the outward effect of both types. But from a medical perspective, visceral fat is the one worth worrying about — and the one that certain peptides target more effectively than others.

Tesamorelin: The Visceral Fat Specialist

If you’re specifically trying to reduce visceral belly fat, tesamorelin has the strongest evidence of any peptide. It’s a growth hormone-releasing hormone (GHRH) analog that stimulates your pituitary gland to produce more growth hormone naturally.

What the Studies Show

Tesamorelin is FDA-approved under the brand name Egrifta for treating excess visceral fat in HIV-infected patients (lipodystrophy). While the approval is narrow, the data on visceral fat reduction is solid.

In a large randomized, double-blind trial published in the New England Journal of Medicine, 404 HIV-positive patients with abdominal fat accumulation received either tesamorelin 2mg daily or placebo. After 26 weeks, the tesamorelin group saw a decrease of 27.8 cm² in visceral adipose tissue, compared to an increase of 5.1 cm² in the placebo group [1].

Extended follow-up showed even better results. At 52 weeks, visceral fat reductions reached approximately 18% from baseline [2]. The fat loss was specifically visceral — subcutaneous fat was relatively unchanged.

A subsequent JAMA-published trial confirmed these findings and added that tesamorelin also produced modest reductions in liver fat, which is closely linked to visceral adiposity [6].

Dosing and Practical Details

The standard dose is 2 mg injected subcutaneously once daily, typically in the abdomen. Results begin appearing around weeks 4-8, with continued improvement through 6-12 months.

The catch: tesamorelin is prescribed off-label for non-HIV patients seeking visceral fat reduction. It requires a prescription and is typically obtained through peptide therapy clinics or compounding pharmacies. Learn more about how tesamorelin compares to other options in our tesamorelin vs semaglutide breakdown.

GLP-1 Peptides: The Biggest Overall Impact

While tesamorelin targets visceral fat specifically, GLP-1 receptor agonists like semaglutide and tirzepatide produce the most total fat loss — belly fat included.

Semaglutide

In the STEP 1 trial, participants on semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% with placebo [3]. Body composition analysis showed that approximately 74% of the weight lost was fat mass.

CT scans from the STEP 1 substudies showed significant reductions in both visceral and subcutaneous abdominal fat. The visceral fat reduction was proportionally greater than subcutaneous, meaning semaglutide does preferentially hit the dangerous belly fat — it just does it by causing overall caloric reduction rather than directly targeting fat cells [7].

Tirzepatide

Tirzepatide (brand name Zepbound for weight loss) goes further. As a dual GIP/GLP-1 receptor agonist, the SURMOUNT-1 trial showed up to 22.5% body weight reduction at the highest dose. For a detailed comparison of these two drugs, see our semaglutide vs tirzepatide guide.

The Trade-off

GLP-1 peptides produce more total weight loss than tesamorelin — there’s no contest on that front. But they work primarily through appetite suppression and slowed gastric emptying. They reduce belly fat as part of reducing everything. Tesamorelin specifically targets visceral fat through the GH pathway. Some clinicians now combine both approaches for patients with significant visceral adiposity [8].

AOD-9604: The GH Fragment

AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191). It was designed to stimulate fat oxidation without the side effects of full growth hormone — particularly without raising blood sugar levels or IGF-1 to problematic levels.

The Evidence Problem

AOD-9604 completed a Phase 2b trial in 300 obese participants. The results were underwhelming: the treatment group lost about 2.6 kg over 12 weeks compared to placebo. The researchers themselves concluded the effect was modest [4].

The peptide never progressed to Phase 3 trials. It is not FDA-approved for any indication. Despite this, it remains widely marketed in the peptide supplements space and prescribed off-label at some clinics.

Does AOD-9604 target belly fat specifically? Some animal studies suggested preferential effects on abdominal adipose tissue, but the human data doesn’t clearly support this claim [9].

Our Take

If you’re considering AOD-9604 for belly fat, understand that the evidence base is thin compared to tesamorelin (FDA-approved, large trials) or semaglutide (massive Phase 3 programs). It may have a role in peptide stacks for fat loss, but don’t expect dramatic results from this peptide alone.

Growth Hormone Peptides: CJC-1295 and Ipamorelin

Growth hormone peptides like CJC-1295 + ipamorelin work by stimulating your pituitary gland to release more GH. Since growth hormone promotes lipolysis (fat breakdown), these peptides are often marketed for belly fat reduction.

What GH Actually Does to Belly Fat

Growth hormone does preferentially mobilize visceral fat over subcutaneous fat. This is well-established physiology. GH-deficient adults have increased visceral adiposity, and GH replacement consistently reduces it [10].

The question is whether the GH increases from secretagogues like CJC-1295 and ipamorelin are large enough to produce meaningful fat loss. Frankly, the direct evidence is limited.

Most of what we know about GH and belly fat comes from studies using pharmaceutical-grade recombinant GH at replacement or supraphysiological doses. Secretagogues produce more modest, pulsatile GH elevations. They may improve body composition over months, but expecting dramatic belly fat reduction from these peptides alone isn’t supported by the current evidence.

When They Make Sense

GH peptides may be most useful as part of a broader protocol — combined with diet, exercise, and potentially other peptides. They also offer additional benefits beyond fat loss, including improved sleep quality and recovery. Read more about how peptides work to understand the GH pathway.

MOTS-c: The Metabolic Peptide

MOTS-c is a newer mitochondrial-derived peptide that’s generating interest for metabolic health. It activates AMPK — the same pathway triggered by exercise and metformin — and has shown effects on fat metabolism and insulin sensitivity in preclinical studies [11].

In mouse models, MOTS-c reduced diet-induced obesity and improved glucose metabolism. It’s been called an “exercise mimetic” because it activates similar cellular pathways to physical activity [12]. For more on how peptides influence metabolic rate, see our peptides for metabolism guide.

However, human clinical data is extremely limited. MOTS-c has entered early-phase clinical trials, but no published results demonstrate belly fat reduction in humans yet. It’s a promising research compound, not a proven therapy.

Comparing the Options

Here’s how the main peptides for belly fat stack up based on current evidence:

Tesamorelin — Strongest evidence for targeted visceral fat reduction. FDA-approved (for lipodystrophy). Reduces visceral fat 15-18% over 6-12 months. Doesn’t cause significant total weight loss.

Semaglutide — Strongest evidence for total weight loss (14.9% body weight). Reduces visceral fat as part of overall fat loss. FDA-approved for obesity.

Tirzepatide — Even greater total weight loss potential (up to 22.5%). Dual mechanism. FDA-approved for obesity.

AOD-9604 — Modest results in Phase 2. Not FDA-approved. Limited belly-fat-specific evidence in humans.

CJC-1295/Ipamorelin — Physiologically plausible for visceral fat reduction through GH pathway. Limited direct clinical evidence for fat loss.

MOTS-c — Interesting metabolic mechanism. No published human fat loss data yet.

For most people seeking to reduce belly fat, the choice comes down to whether you want targeted visceral fat reduction (tesamorelin) or maximum total weight loss that includes belly fat (semaglutide or tirzepatide). Your doctor can help determine which approach fits your situation — find options through peptide therapy online.

Side Effects and Safety

Each peptide class carries different risks. Understanding the side effects of peptides is part of making an informed choice.

Tesamorelin

Common: injection site reactions (pain, redness, itching), joint pain, peripheral edema, increased blood glucose. The IGF-1 increase from tesamorelin raises theoretical concerns about cancer risk in susceptible populations, though clinical trials haven’t shown increased cancer rates [1][2].

GLP-1 Peptides

Common: nausea (especially during dose titration), constipation, diarrhea, injection site reactions. More serious but rare: pancreatitis, gallbladder issues, potential thyroid tumor risk (observed in rodents). Muscle loss during rapid weight loss is a legitimate concern — resistance training during treatment is strongly recommended [3].

AOD-9604

Generally well-tolerated in the limited trial data available. Headache and injection site reactions were reported. Long-term safety data is lacking [4].

GH Peptides (CJC-1295, Ipamorelin)

Common: flushing, headache, dizziness, water retention. These peptides can increase cortisol and prolactin levels transiently. Ipamorelin tends to have fewer side effects than other GH secretagogues because it doesn’t significantly raise cortisol or prolactin.

Always get peptide therapy through a licensed provider. The are peptides safe guide covers broader safety considerations.

FAQ

Do peptides actually target belly fat specifically?▼

Tesamorelin has the best evidence for targeted visceral belly fat reduction — clinical trials show 15-18% decreases using CT imaging. GLP-1 peptides like semaglutide reduce belly fat too, but as part of overall weight loss rather than specific targeting. Growth hormone peptides may preferentially mobilize visceral fat based on GH physiology, but direct clinical proof is limited.

How long do peptides take to reduce belly fat?▼

Timelines vary by peptide. Tesamorelin typically shows measurable visceral fat reduction on imaging within 4-8 weeks, with peak effects at 6-12 months. Semaglutide produces noticeable weight loss (including belly fat) within 4-8 weeks as doses are titrated up, with results continuing to improve through 68 weeks. GH peptides may take 3-6 months for visible body composition changes.

Can I combine peptides for better belly fat results?▼

Some clinicians prescribe tesamorelin alongside GLP-1 peptides for patients with significant visceral fat, using tesamorelin to target belly fat specifically while the GLP-1 handles overall weight management. This is an off-label approach and should only be done under medical supervision. Read about other combination approaches in our peptides for fat loss guide.

Are over-the-counter peptide supplements effective for belly fat?▼

Most over-the-counter peptides marketed for belly fat contain collagen peptides or amino acid blends without clinical evidence for fat reduction. The peptides with actual evidence — tesamorelin, semaglutide, tirzepatide — all require prescriptions. Be skeptical of supplement-grade “fat burning” peptides.

Do I still need to exercise and diet while using peptides for belly fat?▼

Yes. Even the most effective peptides work best alongside proper nutrition and exercise. This is especially true for GH-pathway peptides where the fat-mobilizing effects of growth hormone are enhanced by physical activity. GLP-1 peptides make it easier to maintain a caloric deficit, but resistance training is important to preserve muscle mass during weight loss.

Sources

1. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. doi:10.1056/NEJMoa072375
2. Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. PLoS One. 2010;5(8):e12127.
3. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
4. Stier H, et al. Safety and efficacy of the HGH fragment AOD-9604 in obese subjects. Horm Res. 2004;62(Suppl 2):85.
5. Després JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation. 2012;126(10):1301-1313.
6. Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. doi:10.1001/jama.2014.8334
7. Kosiborod MN, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394-1407.
8. Barb D, et al. Adipose tissue in HIV infection: distribution, metabolic effects, and management strategies. Curr Opin Endocrinol Diabetes Obes. 2022;29(6):520-527.
9. Heffernan MA, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189.
10. Hoffman AR, et al. Growth hormone (GH) replacement therapy in adult-onset GH deficiency: effects on body composition in men and women. J Clin Endocrinol Metab. 2004;89(5):2048-2056.
11. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454.
12. Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.